HALOHalozyme Therapeutics, Inc.

CSNasdaq (XNAS)·USD

Identity

Security key: 16381
Ticker: HALO
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2004-03-12
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: HALO

Detail

Enriched 2026-08-14 20:47

Market cap: $11,552,961,420
Shares outstanding (class): 113,498,000
Shares outstanding (weighted): 113,498,000
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 423
Location: SAN DIEGO, CA
Homepage: https://www.halozyme.com
Description: Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Market cap and share counts drift.

Funds holding this security

275 funds · 280 positions · $2.07B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
iShares Core S&P Mid-Cap ETF iShares Trust	IJH	$251.64M	0.24%	3,893,522 NS	FIGI
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$241.49M	0.01%	3,736,448 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$175.86M	0.11%	2,721,070 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$98.52M	0.25%	1,524,382 NS	FIGI
Disciplined Value Mid Cap Fund John Hancock Funds III	—	$92.25M	0.42%	1,427,415 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$84.86M	0.10%	1,313,072 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$82.37M	1.11%	1,274,489 NS	FIGI
First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund	FBT	$71.92M	3.17%	1,112,843 NS	FIGI
FULLERTHALER BEHAVIORAL SMALL-CAP GROWTH Capitol Series Trust	—	$60.51M	1.44%	936,255 NS	FIGI
State Street SPDR S&P MidCap 400SM ETF Trust —	—	$57.28M	0.24%	886,341 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$56.13M	0.69%	868,502 NS	FIGI
iShares Russell Mid-Cap Growth ETF iShares Trust	IWP	$50.29M	0.27%	778,104 NS	FIGI
iShares S&P Mid-Cap 400 Growth ETF iShares Trust	IJK	$46.15M	0.47%	714,124 NS	FIGI
SMALLCAP World Fund Inc SMALLCAP World Fund Inc	—	$41.52M	0.05%	642,361 NS	FIGI
State Street(R) SPDR(R) Portfolio S&P 400(TM) M… SPDR SERIES TRUST	SPMD	$37.12M	0.24%	574,377 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERHALO
FIGI_COMPOSITEBBG000CZ8W54
FIGI_SHARE_CLASSBBG001SGX585
CIK0001159036
ISINUS40637H1095
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Halozyme is a biopharmaceutical company focused on enzyme-based drug delivery, fitting the biotechnology industry under healthcare.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.